JANE HAYES: Open Payments
NPI 1891384962 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$581 in 29 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $581
Food & beverage: $581
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $169 |
| Otsuka America Pharmaceutical, Inc. | 9 | $162 |
| E.R. Squibb & Sons, L.L.C. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| ABBVIE INC. | 1 | $22 |
| Corium, LLC | 2 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Lundbeck LLC | 1 | $15 |
Products named: INGREZZA, REXULTI, COBENFY, ABILIFY ASIMTUFII, AUSTEDO XR, Qelbree, VRAYLAR, Azstarys.
Industry payments across TX — which companies pay providers there.
